MSB trading, page-3386

Pfeifer1982: haha... we will be here all year splitting hairs about the results from your little cohort group. I am not concerned about our old dosage requirements. I believe that potency has improved with current production methods and that efficacy is more than sufficient to assure MSB of a highly successful  treatment for aGVHD ... (judging by the Colarado Hospital stats). We are now essentially talking about operating margins between two differing production methodologies. My point to you is that first mover advantage will always be key. If we need to use iPS in the future we have our own patent thank you very much .Your posts are improving in their accuracy and becoming a little less biased. I also appreciate your good humour in their delivery  I wish you well. Now we understand each other, I will now move on to other tasks before we bore everyone to death.